CFM
SGMT icon

Catalyst Funds Management’s Sagimet Biosciences SGMT Stock Holding History

Catalyst Funds Management’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,900
Closed -$72.6K – 860
2026
Q1 		$72.6K Buy
+13,900
New +$77.5K 0.01% 514
2024
Q4 		– Sell
-2,600
Closed -$7.2K – 1115
2024
Q3 		$7.2K Sell
2,600
-3,200
-55% -$9.86K ﹤0.01% 1221
2024
Q2 		$19.8K Buy
+5,800
New +$26.6K 0.01% 685

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Catalyst Funds Management's SGMT Position: Q2 2026 in Review

Catalyst Funds Management sold out of Sagimet Biosciences (SGMT) in Q2 2026, closing a stake of 13,900 shares — an estimated $72.6K sold.

Catalyst Funds Management first reported a position in SGMT in Q2 2024 and held it in 3 quarters. The position peaked at $72.6K in Q1 2026. 122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • Catalyst Funds Management reported no remaining Sagimet Biosciences position as of Q2 2026 after selling out during the quarter.
  • Catalyst Funds Management sold 13,900 Sagimet Biosciences shares in Q2 2026, an estimated $72.6K.
  • Catalyst Funds Management first reported a position in Sagimet Biosciences in Q2 2024 and held it in 3 quarters.
  • Catalyst Funds Management's Sagimet Biosciences position peaked at $72.6K in Q1 2026.
  • 122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.